

Alaska Medicaid

**Victrelis™ (boceprevir)**

Available 200mg capsules

**INDICATIONS:**

“VICTRELIS™ is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (≥18 years of age) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.”<sup>1</sup>

**Criteria for Approval:**

1. Diagnosis of chronic hepatitis C genotype 1 infection; **AND**
2. The patient is taking appropriate combination therapy of peginterferon alfa and ribavirin.

**Length of Authorization:**

Coverage may be approved for three months. After three months a new prior authorization must be obtained.

**Dispensing Limit:**

The dispensing limit is a 30 day supply of medication.

**References:**

<sup>1</sup> Victrelis™ prescribing information is available at:  
< [http://www.merck.com/product/usa/pi\\_circulars/v/victrelis/victrelis\\_pi.pdf](http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf) > accessed 12/07/11